Longitudinal follow-up of pure autonomic failure with cardiac sympathetic denervation: Relevance to the body-first theory of Parkinson’s disease
Objective: In this report, we describe eight patients with PAF with nOH and imaging evidence of cardiac sympathetic denervation by 123I-metaiodobenzylguanidine (123I-MBG) single photon emission…Prevalence of depression and cognitive impairment in a Hungarian Parkinson’s disease Center
Objective: Our aim is to determine the prevalence of depression and cognitive impairment (CI) among our PD patients. Background: Depression and CI are the most…Distinct temporal and spatial alteration of immunoproteasome in Parkinson’s Disease pathogenesis
Objective: We aimed to investigate the temporal and spatial evolution of immunoproteasome in the central nervous system (CNS) during PD pathogenesis using mouse model. Background:…Parkinson’s Disease Stigma Questionnaire (PDStigmaQuest): Development and Pilot Study of a Questionnaire for Stigma in Patients with Idiopathic Parkinson’s Disease
Objective: This pilot study aimed to develop and test a stigma questionnaire specific to patients with Parkinson’s disease (PDStigmaQuest). Background: Stigma is significant in PD.…Genetic polymorphisms associated with nigrostriatal dopaminergic depletion as measured with [I123]-FP-CIT SPECT in Parkinson’s disease
Objective: To conduct a genome-wide association study (GWAS) of striatal [I123]-FP-CIT SPECT signal as endophenotype to explore possible associations between genetic background and nigrostriatal dopaminergic…Neurophysiological architecture of visual categorization in early Parkinson’s disease with minor hallucinations
Objective: To explore the neurophysiological dynamics of visual categorization in Parkinson’s disease (PD) with minor hallucinations. Background: Different hypotheses have been proposed for visual hallucinations…Jumping to Conclusions bias, psychosis and impulsivity in early stages of Parkinson’s disease
Objective: The aim was to explore the correlations between Jumping to Conclusions (JtC) tendency and neuropsychiatric features in patients with early Parkinson’s disease (PD). Background:…Innovating Clinical Trial Design to Accelerate Assessment of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Initiative
Objective: To design an optimal multi-arm, multi-stage (MAMS) platform trial for disease-modifying therapies (DMTs) in Parkinson’s disease (PD). Background: The current clinical trials process cannot…Development of therapeutic substances for the disassembly of α-synuclein aggregates as disease-modifying treatment of synucleinopathies
Objective: Development of high-affinity ligands to α-synuclein (α-syn) for a therapeutic approach aiming for the disassembly of α-syn aggregates as a disease-modifying treatment of synucleinopathies.…Novel RAB39B stop mutation in patient with typical Early-Onset Parkinson’s disease
Objective: N/A Background: RAB proteins are small guanosine triphosphatases (GTPases) that are ubiquitous and expressed in all cell types regulating vesicular transport and intracellular membrane…
- « Previous Page
- 1
- …
- 230
- 231
- 232
- 233
- 234
- …
- 436
- Next Page »